Skip to main content
. Author manuscript; available in PMC: 2019 Jan 24.
Published in final edited form as: Gynecol Oncol. 2018 Sep 3;151(2):337–344. doi: 10.1016/j.ygyno.2018.08.008

Fig. 1.

Fig. 1.

OVCAR8 and ARK1 cells are more effectively treated with SQ1274 than paclitaxel. A) Results of XTT assay of relative cell viability in ARK1 and OVCAR8 cells treated with increasing concentrations of paclitaxel and SQ1274. Cell viability is reported relative to controls treated with vehicle. These assays were performed in triplicate and graphed as mean ± SD. *, P < 0.05 compared to controls. B) Western blot analysis of AXL and Gas6 expression in ARK1 and OVCAR8 cell lines treated with vehicle (DMSO), 2 nM paclitaxel, or 2 nM SQ1274. B-actin is shown as a loading control. C) qPCR was performed on cells treated with vehicle, 2 nM paclitaxel or 2 nM SQ1274 and AXL mRNA expression was assessed. Significance was calculated using SD or DDCT. Error bars indicate the range of fold change. **, P < 0.01; ***, P < 0.001.